Alpha Tau Medical Ltd.
DRTS
Cena:
$ 10.04
-0.92 (-8.39%)
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
ALPHA TAU ISSUES LETTER TO SHAREHOLDERS: FIVE CONCURRENT TRIALS IN THE U.S. WITH MULTIPLE SIGNIFICANT VALUE-DRIVING MILESTONES AHEAD
29-01-2026
- EXPECTING VERY ACTIVE 2026 FROM A CLINICAL PERSPECTIVE, INCLUDING SIGNIFICANT PATIENT ACCRUAL COMP...
Více zde
ALPHA TAU REPORTS NEW POSITIVE RESULTS IN TWO UPCOMING PRESENTATIONS AT ASCO GI 2026 SYMPOSIUM SHOWCASING IMMUNE-PRESERVATION AND HIGH DISEASE CONTROL IN MONTREAL PANCREATIC CANCER ALPHA DART® STUDY
06-01-2026
- FINAL RESULTS FROM FIRST PANCREATIC CANCER STUDY IN MONTREAL DEMONSTRATE 81% DISEASE CONTROL RATE,...
Více zde
ALPHA TAU SUBMITS FIRST PRE-MARKET APPROVAL MODULE TO THE FDA FOR ALPHA DART® FOR THE TREATMENT OF RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
05-01-2026
- INITIAL MODULE SUBMISSION MARKS AN IMPORTANT MILESTONE IN THE PRE-MARKET APPROVAL PROCESS - - FL...
Více zde
ALPHA TAU SUCCESSFULLY TREATS FIRST PATIENT IN ITS U.S. TRIAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA AT THE JAMES CANCER HOSPITAL AT THE OHIO STATE UNIVERSITY
09-12-2025
- FIRST PATIENT IN THE WORLD TREATED WITH ALPHA DART ® IN THE BRAIN – - ACCORDING TO THE NATIONAL...
Více zde
ALPHA TAU ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
20-11-2025
- ALPHA DART PANCREATIC CANCER P ATIENT TREATMENTS UNDERWAY IN U.S. MULTI-CENTER PILOT STUDY -...
Více zde
ALPHA TAU TO PARTICIPATE AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON
11-11-2025
JERUSALEM, NOV. 11, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES RECEIPT OF RADIOACTIVE MATERIAL LICENSE FOR ITS NEW HAMPSHIRE MANUFACTURING FACILITY, ADVANCING TOWARDS COMMERCIAL READINESS
21-10-2025
- RECEIPT OF C RITICAL LICENSE MARKS SIGNIFICANT MILESTONE FOR F IRST COMMERCIAL-SCALE MANUFACTURI...
Více zde
ALPHA TAU SUCCESSFULLY TREATS FIRST PATIENT IN ITS U.S. MULTI-CENTER PANCREATIC CANCER CLINICAL TRIAL
02-09-2025
– FIRST PATIENT TREATMENT MARKS SUCCESSFUL INITIATION OF MULTI-CENTER PILOT STUDY IN ALPHA DART U...
Více zde
ALPHA TAU TO PARTICIPATE IN FIVE SEPTEMBER INVESTOR CONFERENCES
27-08-2025
JERUSALEM, AUG. 27, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
11-08-2025
- FDA APPROVAL OF IDE TO CONDUCT A U.S. PILOT STUDY EXPLORING THE USE OF ALPHA DART IN PATIENTS WITH...
Více zde
ALPHA TAU ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
19-05-2025
- INTERIM JAN-2025 RESULTS FROM THREE TRIALS OF ALPHA DART ® IN TREATING PANCREATIC CANCER SHARED A...
Více zde
ALPHA TAU ANNOUNCES APPOINTMENT OF NADAV KIDRON TO ITS BOARD OF DIRECTORS
12-05-2025
JERUSALEM, MAY 12, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS , DRTSW ) ("ALPHA...
Více zde
ALPHA TAU TO PARTICIPATE IN MAY INVESTOR CONFERENCES
06-05-2025
JERUSALEM, MAY 06, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES CLOSING OF $36.9 MILLION REGISTERED DIRECT OFFERING AND STRATEGIC MARKETING ALLIANCE WITH ORAMED PHARMACEUTICALS
28-04-2025
JERUSALEM, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU RECEIVES FDA APPROVAL TO INITIATE A TRIAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
02-04-2025
JERUSALEM, APRIL 02, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS, DRTSW), THE DEVE...
Více zde
ALPHA TAU ANNOUNCES FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
12-03-2025
- INTERIM RESULTS FROM THREE TRIALS EXPLORING THE USE OF ALPHA DART® IN TREATING PANCREATIC CANCER ...
Více zde
ALPHA TAU RECEIVES MEDICAL DEVICE SINGLE AUDIT PROGRAM (MDSAP) CERTIFICATION
24-02-2025
JERUSALEM, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES CORNERSTONE INTERIM DATA ACROSS MULTIPLE CLINICAL TRIALS TO BE SHARED AT R&D UPDATE DAY
27-01-2025
- HIGH DISEASE CONTROL RATE AND STRONG INTERIM SAFETY RESULTS OBSERVED IN PANCREATIC CANCER PATIENTS...
Více zde
ALPHA TAU ANNOUNCES UPCOMING PRESENTATION OF NEW DATA AT 2025 ASCO GI SYMPOSIUM AND AT COMPANY R&D UPDATE DAY
18-12-2024
JERUSALEM, DEC. 18, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES APPOINTMENT OF MAYA NETSER TO ITS BOARD OF DIRECTORS; BOARD MEMBER MEIR JAKOBSOHN STEPPING DOWN, STAYING ON AS ADVISOR
17-12-2024
JERUSALEM, DEC. 17, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS , DRTSW), ("ALPHA ...
Více zde
ALPHA TAU TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
11-12-2024
THE OVERVIEW PRESENTATION WILL REVIEW SOME OF THE COMPANY'S RECENT ACHIEVEMENTS AS WELL AS THE OUTLO...
Více zde
ALPHA TAU TO PARTICIPATE IN LADENBURG'S ONCOLOGY INNOVATORS & INVESTORS SYMPOSIUM
06-12-2024
JERUSALEM, DEC. 06, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU TO PARTICIPATE IN CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE AND PIPER SANDLER'S 36TH ANNUAL HEALTHCARE CONFERENCE
13-11-2024
JERUSALEM, NOV. 13, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES ACCEPTANCE INTO FDA'S TOTAL PRODUCT LIFE CYCLE ADVISORY PROGRAM TO ACCELERATE MARKET ACCESS TO ALPHA DART® FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
21-10-2024
JERUSALEM, OCT. 21, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU TREATS FIRST PATIENT WITH RECURRENT LUNG CANCER
10-10-2024
JERUSALEM, OCT. 10, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU ANNOUNCES FDA APPROVAL OF IDE TO INITIATE MULTI-CENTER INVESTIGATOR-INITIATED STUDY OF ALPHA DART® IN IMMUNOCOMPROMISED PATIENTS WITH RECURRENT CSCC
20-09-2024
-TRIAL TO FOCUS ON PARTICULARLY VULNERABLE SUBSET OF PATIENTS, FOLLOWING STRONG CLINICIAN INTEREST I...
Více zde
ALPHA TAU TO PARTICIPATE IN THE H.C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE, THE SIDOTI SMALL-CAP VIRTUAL INVESTOR CONFERENCE, THE REDBURN ATLANTIC AND ROTHSCHILD & CO 2024 RADIOPHARMA CONFERENCE, AND THE LYTHAM PARTNERS FALL 2024 INVESTOR CO
22-08-2024
JERUSALEM, AUG. 22, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
ALPHA TAU MEDICAL ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
14-08-2024
- FIRST PATIENT TREATED IN MAY FOR LIVER METASTASES FROM COLORECTAL CANCER - - PUBLICATION IN JUNE I...
Více zde
ALPHA TAU ANNOUNCES PUBLICATION IN CANCERS JOURNAL OF LONG-TERM SAFETY AND EFFICACY DATA IN MULTIPLE HARD-TO-TREAT SUPERFICIAL CANCERS
25-06-2024
THE POOLED ANALYSIS INCLUDED DATA FROM 4 I NTERNATIONAL CLINICAL TRIALS SPANNING A N ARRAY OF HARD-T...
Více zde
ALPHA TAU TO PRESENT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE
21-05-2024
JERUSALEM, MAY 21, 2024 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE “COMPANY...
Více zde
Dokumenty nejsou k dispozici
